Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Section of Psychiatry, University of Verona, P.le Scuro 10, 37134, Verona, VR, Italy.
Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy.
Sci Rep. 2022 Dec 30;12(1):22603. doi: 10.1038/s41598-022-27046-5.
Identifying factors that influence problematic beliefs and behaviors related to pharmacotherapy may be useful for clinicians to improve the patients' adherence. The study aims to assess patients' beliefs about the necessity and concerns regarding pharmacotherapy in rheumatic diseases and attitude styles, and to investigate the association between clinical factors and negative beliefs about medication. A sample of 712 patients affected by Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis was enrolled. They were assessed using the Beliefs about Medicines Questionnaires-Specific (BMQ), the Simplified Disease Activity Index (SDAI), the Visual Analogue Scale for pain (VAS), the Chalder Fatigue Scale (CFQ) and the Health Assessment Questionnaire-Disability Index (HAQ-DI). The balance between benefits and costs in the BMQ-Specific was positive in the 79.4% of patients, negative in the 12.1% and equal in the 8.6%. SDAI, taking more than 5 medications, taking anti interleukin 6 (Anti-IL6) or biological disease-modifying antirheumatic drugs (bDMARDs), or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), pain, and fatigue were significantly associated to higher Concerns. Having a longer disease duration was significantly associated with a higher Necessity, together with the current pharmacological treatments and the disability. The multivariate regression models estimated that higher pain and fatigue were associated to higher Concerns (p < 0.001), while a longer disease duration (p < 0.001) and all pharmacological treatments for a rheumatologic disease (p = 0.001) were associated to higher Necessity levels. A high length of disease, a low level of remission, a high number of total medications, the prescription of an Anti-IL6/bDMARDs/tsDMARDs drug, a high level of pain, fatigue and disability identified patients potentially less adherent to pharmacotherapy to be carefully looked after by clinicians.
确定影响与药物治疗相关的问题信念和行为的因素可能对临床医生改善患者的依从性有用。本研究旨在评估患者对风湿病药物治疗的必要性和关注的信念,以及态度风格,并调查临床因素与对药物的负面信念之间的关联。纳入了 712 名患有类风湿关节炎、银屑病关节炎、强直性脊柱炎的患者。他们使用药物信念问卷-特定版(BMQ-Specific)、简化疾病活动指数(SDAI)、疼痛视觉模拟量表(VAS)、查尔德疲劳量表(CFQ)和健康评估问卷残疾指数(HAQ-DI)进行评估。在 BMQ-Specific 中,益处与成本之间的平衡在 79.4%的患者中为正,在 12.1%的患者中为负,在 8.6%的患者中为相等。SDAI、服用超过 5 种药物、服用抗白细胞介素 6(Anti-IL6)或生物改善病情抗风湿药物(bDMARDs)或靶向合成改善病情抗风湿药物(tsDMARDs)、疼痛和疲劳与更高的关注显著相关。疾病持续时间较长与更高的必要性显著相关,同时与当前的药物治疗和残疾相关。多变量回归模型估计,更高的疼痛和疲劳与更高的关注相关(p<0.001),而更长的疾病持续时间(p<0.001)和所有用于治疗风湿病的药物(p=0.001)与更高的必要性水平相关。疾病的长期长度、低缓解水平、总药物数量的增加、抗白细胞介素 6/bDMARDs/tsDMARDs 药物的处方、高疼痛水平、疲劳和残疾确定了潜在的药物治疗依从性较低的患者,临床医生需要对其进行仔细的照顾。